Back to top
more

MariMed Inc. (MRMD)

(Delayed Data from OTC)

$0.18 USD

0.18
718,310

+0.02 (11.11%)

Updated Sep 9, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MRMD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

MariMed Inc. [MRMD]

Reports for Purchase

Showing records 1 - 20 ( 21 total )

Company: MariMed Inc.

Industry: Consulting Services

Record: 1

08/08/2024

Company Report

Pages: 7

Operational Wins, But Mixed Q2/24 Results As Costs Continue to Climb

Provider: Ventum Capital Markets

Analyst: SEMPLE A

Price: 25.00

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 2

05/13/2024

Industry Report

Pages: 19

Cannabis Market Highlights

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 50.00

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 3

05/09/2024

Company Report

Pages: 7

Costs Weigh on Q124 Earnings, Though H224 Still Expected to Show

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 25.00

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 4

03/07/2024

Company Report

Pages: 9

Q423 Results Below Expectations

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 25.00

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 5

11/20/2023

Company Report

Pages: 6

New Debt Facility Improves Liquidity Outlook, Positive for Shareholders

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 6

11/09/2023

Company Report

Pages: 8

Q323 Results Mixed

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 7

11/09/2023

Company Report

Pages: 8

Q323 Results Mixed

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 8

08/03/2023

Company Report

Pages: 7

Back Half Better than the Front Half

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 9

05/09/2023

Company Report

Pages: 8

Solid Q123 Results and Outlook Maintained

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 10

03/02/2023

Company Report

Pages: 8

Solid Q422 Results and 2023 Guidance Ahead of Estimates, Cashed Up for Tuck-in M&A and Maryland Adult-Use Could Drive Further Upside

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 11

02/25/2023

Industry Report

Pages: 8

Weekly ReHash: Cannabis Week - Earnings Preview

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 12

02/05/2023

Industry Report

Pages: 11

Weekly ReHash: Cannabis - Year of Resiliency

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 13

01/30/2023

Company Report

Pages: 6

Savvy to Beef Up the Balance Sheet While Others Pull Back From the Dinner Table, Expecting Tuck-In M&A and Accelerated Growth Capex to Follow

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 14

01/15/2023

Industry Report

Pages: 9

Weekly ReHash: Pricing is Key to Improving Industry Fundamentals

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 15

11/08/2022

Company Report

Pages: 7

Mixed Q322 Results: Sales Outpacing Markets but Pricing Pressure Limits Margin Recovery; Revised Guidance Pushes Profitability Ramp to 2023

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 16

10/05/2022

Company Report

Pages: 5

Achieves Vertical Integration in Maryland Ahead of Likely Adult-Use Approval, Valuation Offers Attractive Entry Point

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 5.00

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 17

08/09/2022

Company Report

Pages: 7

Solid Q222 Sales But Surprise Margin Blip and Revised Guidance, Expecting Sales Growth and Higher Earnings in H222

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 18

05/11/2022

Company Report

Pages: 7

Q421 Results Strong Across the Board: Setting a High Standard in a Seasonally Weak Quarter

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 19

04/28/2022

Company Report

Pages: 9

Closes Acquisition of Kind Therapeutics, Consolidating Maryland Business Ahead of Likely Adult-Use Conversion

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: MariMed Inc.

Industry: Consulting Services

Record: 20

03/17/2022

Company Report

Pages: 8

Q421 Results & Site Visit Notes: Solid Revenues, Margins a Tad Light but Reasons for Improvement Across 2022

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party
// eof